Docket #: S21-211
Thiourea-enhanced antimicrobial peptoids as a treatment against antibiotic resistant microbes
Antimicrobial peptoids are promising leads for novel antibiotics; however, their activity is often compromised under physiological conditions. Inventors at Stanford enhanced the efficacy of antimicrobial peptoids by using thiourea and thiourea derivatives. The minimum inhibitory concentration (MIC) of antimicrobial peptoids against Pseudomonas aeruginosa, Staphylococcus aureus, and Ciprofloxacin-resistant Klebsiella pneumoniae significantly decreased when determined in the presence of thiourea as compared to antimicrobial peptoid only. In addition, combination with thiourea enhances the efficacy of antimicrobial peptoids against bacterial biofilms. The combination of thiourea with antimicrobial peptoids has potential to be used in therapeutic applications to treat acute and chronic bacterial infections.
Applications
- Antibiotic medications
- Antibacterial products
Advantages
- Enhances efficacy of treatment against antibiotic-resistant bacteria
- Can be used with gram-positive and gram-negative bacteria
- Does not synergize with the peptoid, preventing unwanted mutations to the compound
Patents
- Published Application: WO2023288065
- Published Application: 20240316141
Similar Technologies
-
A method for the construction of aminocyclobutanes from copper-catalyzed aqueous [2+2] cycloadditions of unactivated olefins S22-298A method for the construction of aminocyclobutanes from copper-catalyzed aqueous [2+2] cycloadditions of unactivated olefins
-
Explainable Computational Methods for Predicting Treatment Response to Immunotherapy from Histology Images of Non-Small-Cell Lung Cancer S24-079Explainable Computational Methods for Predicting Treatment Response to Immunotherapy from Histology Images of Non-Small-Cell Lung Cancer
-
Bio-engineered mitochondria for targeted delivery to cells, tissue, and organs S24-026Bio-engineered mitochondria for targeted delivery to cells, tissue, and organs